礼来公布口服GLP-1RA III期临床结果，肥胖适应症预计今年在美提交

时代财经2025-08-26

本文来源：时代财经8月26日晚间，时代财经获悉，礼来制药公布了每日一次口服小分子GLP-1受体激动剂orforglipron的III期临床试验ATTAIN-2的积极顶线结果。这一项针对合并2型糖尿病的肥胖或超重成人患者的研究显示，orforglipron的3个剂量组均达到了主要终点和所有关键次要终点，在72周时实现了显著的体重下降、具有临床意义的糖化血红蛋白（A1C）降低，及心血管风险因素的改善。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2562851736?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-26 20:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2562851736","market":"us","top_or_hot":-1,"title":"礼来公布口服GLP-1RA III期临床结果，肥胖适应症预计今年在美提交","media":"时代财经","content":"<div>\n<p>本文来源：时代财经8月26日晚间，时代财经获悉，礼来制药公布了每日一次口服小分子GLP-1受体激动剂orforglipron的III期临床试验ATTAIN-2的积极顶线结果。这一项针对合并2型糖尿病的肥胖或超重成人患者的研究显示，orforglipron的3个剂量组均达到了主要终点和所有关键次要终点，在72周时实现了显著的体重下降、具有临床意义的糖化血红蛋白（A1C）降低，及心血管风险因素的改善。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082620085194fde36f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来公布口服GLP-1RA III期临床结果，肥胖适应症预计今年在美提交</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来公布口服GLP-1RA III期临床结果，肥胖适应症预计今年在美提交\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-26 20:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082620085194fde36f&s=b><strong>时代财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>本文来源：时代财经8月26日晚间，时代财经获悉，礼来制药公布了每日一次口服小分子GLP-1受体激动剂orforglipron的III期临床试验ATTAIN-2的积极顶线结果。这一项针对合并2型糖尿病的肥胖或超重成人患者的研究显示，orforglipron的3个剂量组均达到了主要终点和所有关键次要终点，在72周时实现了显著的体重下降、具有临床意义的糖化血红蛋白（A1C）降低，及心血管风险因素的改善。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082620085194fde36f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082620085194fde36f&s=b","article_id":"2562851736","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082620085194fde36f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2562851736","pubTimestamp":1756209973,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"本文来源：时代财经8月26日晚间，时代财经获悉，礼来制药公布了每日一次口服小分子GLP-1受体激动剂orforglipron的III期临床试验ATTAIN-2的积极顶线结果。据悉，礼来计划于2025年向美国食品药品管理局提交 orforglipron用于肥胖症治疗的上市许可申请，并于2026年初针对糖尿病治疗启动申报流程。此外，礼来全球高级副总裁、礼来中国药物开发及医学事务中心负责人王莉博士表示，中国已同步加入了orforglipron的全球研发，期待 orforglipron 能早日在中国获批，为中国患者带来新的治疗选择。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LLY":"礼来","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","III":"信息服务","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4144":"石油与天然气的储存和运输","BK4599":"减肥药","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","GLP":"Global Partners Lp","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999001176.USD":"United Global Healthcare Acc USD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD"},"translate_title":"Eli Lilly announces oral GLP-1RA phase III clinical results, and obesity indications are expected to be submitted in the United States this year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1,"LLY":1,"III":1},"content_text":"本文来源：时代财经8月26日晚间，时代财经获悉，礼来制药公布了每日一次口服小分子GLP-1受体激动剂orforglipron的III期临床试验ATTAIN-2的积极顶线结果。这一项针对合并2型糖尿病的肥胖或超重成人患者的研究显示，orforglipron的3个剂量组均达到了主要终点和所有关键次要终点，在72周时实现了显著的体重下降、具有临床意义的糖化血红蛋白（A1C）降低，及心血管风险因素的改善。在主要终点方面，每日一次且在不受食物或饮水限制的前提下，orforglipron 36mg组平均体重下降达10.5%（10.4 kg），而安慰剂组为2.2%（2.3 kg）（使用有效性估计目标）。据悉，礼来计划于2025年向美国食品药品管理局（FDA）提交 orforglipron用于肥胖症治疗的上市许可申请，并于2026年初针对糖尿病治疗启动申报流程。此外，礼来全球高级副总裁、礼来中国药物开发及医学事务中心负责人王莉博士表示，中国已同步加入了orforglipron的全球研发，期待 orforglipron 能早日在中国获批，为中国患者带来新的治疗选择。（时代财经 张羽岐）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2562851736","isCrawlerRequest":true}